The traditional Chinese medicine sector changed again, and many stocks rose by the daily limit

[Pharmaceutical Network Pharmaceutical Stock Market] On January 5th, the traditional Chinese medicine sector changed again.
As of 10:37, many stocks such as Wohua Medicine continued to trade at their daily limit.
In addition, Essence Pharmaceuticals rose by nearly 10%, and Zixin Pharmaceuticals rose by more than 6%
.

As of 10:37, Wohua Medicine continued to trade at the daily limit, which was previously at 9:26
.

The stock is currently at 8.
95 yuan, with a turnover of 193 million and a turnover rate of 3.
82%
.

Regarding the reasons for the change of the stock, the analysis believes that, first, the company is the first pharmaceutical company to disclose the 2021 annual report, and will disclose the "2021 Annual Report" on January 21, 2022
.

Second, the company is a major domestic manufacturer of pure natural plant-based cardiovascular and cerebrovascular Chinese patent medicines with a century-old history
.

 　　Essence Pharma opened the daily limit at intraday on January 5, and is now at 13.
63 yuan, an increase of 9.
83%, with a turnover of 1.
923 billion and a turnover rate of 17.
39%
.

The stock has risen by the limit 13 times in the past year
.

The company is mainly engaged in the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals
.

It is worth mentioning that Essence Pharmaceuticals has recorded 9 daily limits within 10 trading days, with a cumulative increase of 127.
50% and a cumulative turnover rate of 52.
00%
.

 　　In addition, Zixin Pharmaceutical also hit the daily limit today.
The stock has closed 3 daily limit in a row, and is now at 3.
99 yuan, an increase of 5.
84%, with a turnover of 1.
199 billion and a turnover rate of 23.
05%
.

The stock has risen by the limit 7 times in the past year
.

According to the data, the company's main business is Chinese patent medicine industry, ginseng industry, and industrial hemp industry
.

In the news, the company recently signed an "Entrustment Agreement" with Beidahuang Kenfeng Seed Industry Co.
, Ltd.
, entrusting it to introduce 20kg of industrial hemp seeds with the variety name FG230519HJ from the Netherlands to China
.

 　　For the traditional Chinese medicine industry, on December 30, 2021, the two departments issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine", clearly giving full play to the advantages of the medical insurance system and supporting the inheritance, innovation and development of traditional Chinese medicine; on the same day, the national The Food and Drug Administration issued the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" to accelerate China's leap from a pharmaceutical powerhouse to a pharmaceutical powerhouse to better meet the health needs of the people; in addition, recently, Shanghai, Zhejiang and Jiangxi 7 provinces including Shandong, Hunan, Guangdong, and Sichuan have received news that they have been approved to build a national demonstration zone for comprehensive reform of traditional Chinese medicine
.

It is reported that the National TCM Comprehensive Reform Demonstration Zone takes the provinces (autonomous regions and municipalities) as the main body of construction, and encourages pilot trials in TCM service models, industrial development, and quality supervision
.

 　　Galaxy Securities believes that multi-factor resonance drives the return of the value of branded traditional Chinese medicine, including: national policies continue to support the development of the traditional Chinese medicine industry; the price reduction for centralized procurement of proprietary Chinese medicines is moderate, in line with expectations; The increase in the ex-factory prices of oral liquids has aroused the market's attention to the price-raising ability of branded traditional Chinese medicines, which have the ability to increase prices
.

 　　Sinolink Securities also pointed out that with the promotion of favorable policies for many years, the traditional Chinese medicine industry has ushered in new opportunities
.

In addition, products such as proprietary Chinese medicines are included in the scope of centralized procurement, which is expected to promote the admission of traditional Chinese medicines to hospitals and broaden the channels for increasing the volume
.

The aging process and the increase in the incidence of chronic diseases continue to promote market expansion.
The epidemic situation and policy support have improved the consumer recognition of traditional Chinese medicine and gradually revealed its consumption attributes
.

With the intensification of population aging, the base of chronic disease patients continues to expand, and the rigid demand for traditional Chinese medicine continues to grow
.

Brand traditional Chinese medicine OTC is expected to usher in development opportunities
.

 　　In addition, Huaan Securities stated that 2021 is the year of the outbreak of the traditional Chinese medicine industry
.

Judging from the annual rise and fall data, the Shenwan traditional Chinese medicine sector has risen by 28.
84% throughout the year, but the traditional Chinese medicine sector is not overvalued, and 2022 will be a key year for real performance and logic
.